GLP-1 receptor agonists began as diabetes drugs, became the biggest story in weight care, and are now being studied for something bigger: whether they bend the curve on the diseases that end healthspan.
Beyond the scale
The headline finding wasn’t the weight loss. In the SELECT trial — 17,000+ adults with cardiovascular disease and elevated weight, no diabetes — semaglutide cut major cardiovascular events by roughly 20%. Follow-on analyses point the same direction for kidney outcomes and heart failure symptoms.
Mechanistically that tracks: sustained fat-mass reduction lowers blood pressure, ApoB, inflammatory tone (hs-CRP), and insulin resistance at the same time. Those are four of the biggest levers in all of preventive medicine, moved at once.
The honest caveats
- Lean mass: rapid loss takes muscle with it unless you train and eat protein deliberately. For longevity, strength is not optional.
- Durability: stop the drug without changing the system around it, and most weight returns within a year.
- Selection: trial populations were high-risk. If you’re lean and metabolically healthy, there is no evidence GLP-1s add years.
- Side effects: GI symptoms are common early; rarer risks deserve a real clinical conversation, not a group chat.
We treat GLP-1s as a powerful tool with a narrow job: correcting metabolic disease that diet and training haven’t moved — always paired with resistance training, protein targets, and re-testing. A tool, not a plan.
What we watch on re-test
Members on metabolic protocols re-test ApoB, fasting insulin, HbA1c, hs-CRP, liver enzymes, and body composition — not just weight. The scale is the least interesting number on the panel.
Key references: SELECT trial (semaglutide, NEJM 2023); SURMOUNT program (tirzepatide); FLOW trial (kidney outcomes, 2024). Concept brand — not medical advice; GLP-1 therapy requires clinical supervision.
